DHCR24 and metabolic dysfunction-associated steatohepatitis: In this study, we exploited the synthetic DHCR24 inhibitor SH42, developed by our group (Muller et al, 2017), for the treatment of hepatic steatosis and inflammation, that is, the two hallmarks of NAFLD/NASH development.